DISEASE / DISORDER	Price (£)	Routine TAT (Calendar days)	Gene(s) or locus	Description of test (including reference intervals/ clinical decision values where applicable)	Category
CYTOGENETIC TESTS					
Fetal loss referrals: Common aneuploidy testing R22.1, R318.1 Microarray analysis R22.2, R318.2 Karyotype R297.1 FISH	195 410 280 280	42 42 42 42	Chr 13, 18, 21, X, Y Genome-wide CNVs Targeted probe	QF PCR Analysis, interpreting and reporting G banding FISH	
Postnatal cytogenetic referrals: Common aneuploidy testing R26.1 Microarray (multiple indications) Targeted follow up testing R375.1 Karyotype R297.1 FISH	195 410 195 280 280	N/A 3 ¹ /42 42 42 42 42 42 ¹ urgent		QF PCR Analysis, interpreting and reporting Microarray analysis or FISH G banding FISH	
MOLECULAR GENETIC TESTS		neonates			
Albinism or congenital nystagmus R39	840	84	23-gene panel	Next-generation sequencing	NGS service
TYR and OCA2 dosage analysis*	120	42	TYR, OCA2	MLPA	Targeted mutation test
Albright hereditary osteodystrophy, pseudohypoparathyroidism and pseudopseudohypoparathyroidism Methylation testing R293.2	230	42	GNAS	MS-MLPA	Imprinting analysis
UPD(20) follow-up R263	340	42	No specific gene	Microsatellite analysis	
GNAS sequencing R293.1	440	42	GNAS	NGS + Sanger sequencing	Single gene screen

Alpha 1 - antitrypsin deficiency R191	230	42	SERPINA1	Two common mutations (S & Z)	Targeted mutation test	
Angelman syndrome R47					Imprinting analysis	
Chromosome 15 abnormalities	230	42	<i>SNURF</i> :TSS-DMR	MS-MLPA		
UPD(15) follow-up R263	340	42	No specific gene	Microsatellite analysis		
Aortopathy panel	See Tho	racic aortic a	neurysm or dissection			
Beckwith-Wiedemann syndrome R49 ; isolated hemihypertrophy or macroglossia R50						
Chromosome 11 abnormalities (ICR1 and ICR2)	230	42	H19-IGF2:IG-DMR, KCNQ1OT1:TSS-DMR	MS-MLPA	Imprinting analysis	
UPD(11) follow-up R263	340	42	11p15.5	Microsatellite analysis		
CDKN1C sequencing R49.3	350	42	CDKN1C	Sanger sequencing	Single gene screen	
Blepharophimosis, ptosis and epicanthus inversus (BPES) R43	460	42	FOXL2	Full mutation screen + MLPA + fragment analysis	Single gene screen	
Breast/ovarian cancer	See Inherited breast cancer and ovarian cancer					
Ovarian cancer	See Inherited ovarian cancer (without breast cancer)					
Chronic myeloid leukaemia (CML)	See Oncology genetics page on our website					
Chronic lymphoblastic leukaemia (CLL)	See Oncology genetics page on our website					
Cowden syndrome	See PTEN hamartoma tumour syndrome					
Cystic fibrosis Routine diagnostic or carrier testing R184.1 , R185.1	205	42	CFTR	50 most common UK mutations	Targeted mutation test	
Urgent carrier testing R185.1	205	14	CFTR	50 most common UK mutations		
Newborn screen from blood spots R253	120	4 working days	CFTR	4 most common mutations in the UK		

Factor V Leiden and Prothrombin mutations*	230	42	F5, F2	NGS genotyping	Targeted mutation	
Familial testing for known variants					test Targeted mutation	
Predictive testing R242	Dlease	send to ann	ory for the familial condition (for	test		
Carrier testing R244			oratory (for core tests)	test		
Parental/segregation testing R375	Special	131 163137 01				
Haematological malignancies	See On	cology gene	etics page on our website		1	
Haemochromatosis	See Iro	n overload -	 hereditary haemochroma 	tosis testing		
Hypogonadotropic hypogonadism R148						
14-gene panel	840	84	14-gene panel	Next-generation sequencing	NGS service	
Inherited breast cancer and ovarian cancer R208	735	42	BRCA1, BRCA2, PALB2	Next-generation sequencing	NGS service	
				+ MLPA for BRCA1 and BRCA2		
Inherited ovarian cancer (without breast cancer)	840	42	8-gene panel	Next-generation sequencing	NGS service	
R207				+ MLPA for BRCA1 and BRCA2		
Iron overload – hereditary haemochromatosis	230	42	HFE	Two common mutations	Targeted mutation	
testing R95					test	
Kagami-Ogata syndrome R268					Imprinting analysis	
Methylation abnormalities	230	42	<i>MEG3:</i> TSS-DMR	Methylation-sensitive MLPA		
Paternal UPD(14) follow-up R263	340	42	No specific gene	Microsatellite analysis		
Kallmann syndrome	See Hypogonadotropic hypogonadism					
Marfan syndrome	See Thoracic aortic aneurysm or dissection					
Multi-locus imprinting disorder*	230	42	No specific gene	Methylation-sensitive MLPA for	Imprinting analysis	
				chromosomes 6, 7, 11, 14, 15 and	, ,	
				20		
Myeloproliferative neoplasia (MPN)	See On	•				
Neurofibromatosis type 1 (NF1) R222	735	42	NF1, SPRED1	Next-generation sequencing	NGS service	
(including Legius syndrome*)				+ MLPA for NF1		
Noonan syndrome*					NGS service	
Full screen	840	84	14-gene panel	Next-generation sequencing		

Data analysis only	330	84	14-gene panel	Next-generation sequencing (data)		
Oculopharyngeal muscular dystrophy (OPMD) R75	120	42	PABPN1	Fluorescent PCR (Normal: 10 repeats; Pathogenic: 11-17 repeats)	Repeat expansion test	
Prader-Willi syndrome R48					Imprinting analysis	
Chromosome 15 abnormalities	230	42	<i>SNURF</i> :TSS-DMR	MS-MLPA		
UPD(15) follow-up R263	340	42	No specific gene	Microsatellite analysis		
Prenatal testing for known pathogenic variants*	Please .	send to appro	opriate specialist laborato	ory for the familial condition (for	Targeted mutation	
	specialist tests) or to the designated GLH laboratory (for core tests)				test	
Primary ciliary dyskinesia (PCD)	See Res	See Respiratory ciliopathies				
Pseudohypoparathyroidism (PHP)	See Albright hereditary osteodystrophy					
PTEN hamartoma tumour syndrome R213	460	42	PTEN	Mutation screening by NGS + MLPA	NGS service	
Respiratory ciliopathies including non-CF bronchiectasis R189	1000	84	46-gene panel	Next-generation sequencing	NGS service	
RNA studies (investigating the effect of sequence variants on splicing) R296	585	42	No specific gene	Analysis of DNA variants for splicing abnormalities	Specialised testing	
Russell-Silver syndrome	See Silv					
Sequencing of known variants (confirmations, family or predictive testing)	Please send to appropriate specialist laboratory for the familial condition (for specialist tests) or to the designated GLH laboratory (for core tests)				Targeted mutation test	
Silver-Russell syndrome (Growth failure in early childhood) R147.2 Chromosome 11 abnormalities (ICR1 only) and UPD(7) analysis	230	42	H19-IGF2:IG-DMR, GRB10:alt-TSS-DMR,	MS-MLPA	Imprinting analysis	
UPD(11) follow-up R263	340	42	MEST:alt-TSS-DMR No specific gene	Microsatellite analysis		
Thoracic aortic aneurysm or dissection (TAAD) R125	1000	84	32-gene panel	Next-generation sequencing + MLPA for FBN1 only	NGS service	

Temple syndrome R267					Imprinting analysis
Methylation abnormalities	230	42	MEG3:TSS-DMR	MS-MLPA	
A4.1	240	42	Nie was 200 a sa a sa	Address and Hitter and Late	
Maternal UPD(14) follow-up R263	340	42	No specific gene	Microsatellite analysis	
Transient neonatal diabetes mellitus (TNDM)	230	42	PLAGL1:alt-TSS-DMR	6q24 methylation, UPD and dosage	Imprinting analysis
(6q24-related neonatal diabetes, R143.3)				analysis by MLPA	
UPD(6) follow-up R263	340	42	No specific gene	Microsatellite analysis	
Uniparental disomy confirmation R263	570	42	No specific gene	Microsatellite analysis	UPD confirmation
(where no prior imprinting analysis at WRGL)					
X-inactivation studies R111	230	42	No specific gene	Methylation analysis by restriction	Specialised testing
				enzyme digestion	
				(Random = <80:20 ratio; skewed =	
				>91:9 ratio).	